{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:57:07Z","timestamp":1787234227093,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00415-024-12803-5","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T13:59:28Z","timestamp":1734789568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3596-9515","authenticated-orcid":false,"given":"Mihaela","family":"Nicolescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"H\u00e4u\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike Cosima","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith Bellmann","family":"Strobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Krumbholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"H\u00fcmmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"B\u00fctow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Tkachenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Trebst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Ayzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Schwake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thivya","family":"Pakeerathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katinka","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ringelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-9255","authenticated-orcid":false,"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kaste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Angstwurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Giglhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Then Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makbule","family":"Senel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Vardakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dawin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Revie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Korporal-Kuhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Jarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-6987","authenticated-orcid":false,"given":"Daniel","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4386-1340","authenticated-orcid":false,"given":"Joachim","family":"Havla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Stolowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Patrick","family":"Stellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Neuromyelitis Optica Study Group (NEMOS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"9","key":"12803_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","volume":"20","author":"R Marignier","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20(9):762\u2013772. https:\/\/doi.org\/10.1016\/S1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"issue":"3","key":"12803_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol 22(3):268\u2013282. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"issue":"2","key":"12803_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"2","key":"12803_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","volume":"176","author":"S Jarius","year":"2014","unstructured":"Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176(2):149. https:\/\/doi.org\/10.1111\/cei.12271","journal-title":"Clin Exp Immunol"},{"key":"12803_CR5","doi-asserted-by":"publisher","unstructured":"Jarius S, Aktas O, Ayzenberg I, et al (2023) Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol 270(7):3341\u20133368. https:\/\/doi.org\/10.1007\/s00415-023-11634-0","DOI":"10.1007\/s00415-023-11634-0"},{"issue":"1","key":"12803_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15(1):134. https:\/\/doi.org\/10.1186\/s12974-018-1144-2","journal-title":"J Neuroinflammation"},{"issue":"12","key":"12803_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold A, Fraser CL, Abegg M et al (2022) Diagnosis and classification of optic neuritis. Lancet Neurol 21(12):1120\u20131134. https:\/\/doi.org\/10.1016\/S1474-4422(22)00200-9","journal-title":"Lancet Neurol"},{"issue":"5","key":"12803_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamaophthalmol.2021.0146","volume":"139","author":"L Assi","year":"2021","unstructured":"Assi L, Chamseddine F, Ibrahim P et al (2021) A global assessment of eye health and quality of life: a systematic review of systematic reviews. JAMA Ophthalmol 139(5):526\u2013541. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.0146","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"12803_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1212\/WNL.0b013e318299ccd9","volume":"81","author":"E Garcia-Martin","year":"2013","unstructured":"Garcia-Martin E, Rodriguez-Mena D, Herrero R et al (2013) Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS. Neurology 81(1):76\u201383. https:\/\/doi.org\/10.1212\/WNL.0b013e318299ccd9","journal-title":"Neurology"},{"issue":"12","key":"12803_CR10","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1177\/1352458513479840","volume":"19","author":"L Jasse","year":"2013","unstructured":"Jasse L, Vukusic S, Durand-Dubief F et al (2013) Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler Houndmills Basingstoke Engl 19(12):1618\u20131626. https:\/\/doi.org\/10.1177\/1352458513479840","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"12803_CR11","doi-asserted-by":"publisher","unstructured":"Backner Y, Petrou P, Glick-Shames H, et al (2019) Vision and vision-related measures in progressive multiple sclerosis. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2019.00455","DOI":"10.3389\/fneur.2019.00455"},{"issue":"6","key":"12803_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/1352458517708463","volume":"24","author":"LJ Balk","year":"2018","unstructured":"Balk LJ, Coric D, Nij Bijvank JA, Killestein J, Uitdehaag BM, Petzold A (2018) Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 24(6):767\u2013776. https:\/\/doi.org\/10.1177\/1352458517708463","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"11","key":"12803_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/jnnp-2023-331183","volume":"94","author":"SC Rosenkranz","year":"2023","unstructured":"Rosenkranz SC, Gutmann L, Has Silemek AC et al (2023) Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 94(11):924\u2013933. https:\/\/doi.org\/10.1136\/jnnp-2023-331183","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"12803_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2377-14-31","volume":"14","author":"J Schinzel","year":"2014","unstructured":"Schinzel J, Zimmermann H, Paul F et al (2014) Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurol 14(1):31. https:\/\/doi.org\/10.1186\/1471-2377-14-31","journal-title":"BMC Neurol"},{"key":"12803_CR15","doi-asserted-by":"publisher","unstructured":"Rosenkranz SC, Kaulen B, Zimmermann HG, Bittner AK, Dorr M, Stellmann JP. (2021) Validation of computer-adaptive contrast sensitivity as a tool to assess visual impairment in multiple sclerosis patients. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2021.591302","DOI":"10.3389\/fnins.2021.591302"},{"issue":"2","key":"12803_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.614","volume":"7","author":"JP Stellmann","year":"2017","unstructured":"Stellmann JP, Cetin H, Young KL et al (2017) Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing-remitting MS. Brain Behav 7(2):e00614. https:\/\/doi.org\/10.1002\/brb3.614","journal-title":"Brain Behav"},{"issue":"11","key":"12803_CR17","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1002\/hbm.25440","volume":"42","author":"AC Has Silemek","year":"2021","unstructured":"Has Silemek AC, Ranjeva JP, Audoin B et al (2021) Delayed access to conscious processing in multiple sclerosis: reduced cortical activation and impaired structural connectivity. Hum Brain Mapp 42(11):3379\u20133395. https:\/\/doi.org\/10.1002\/hbm.25440","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"12803_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1212\/WNL.0000000000004060","volume":"89","author":"S Batista","year":"2017","unstructured":"Batista S, Alves C, d\u2019Almeida OC et al (2017) Disconnection as a mechanism for social cognition impairment in multiple sclerosis. Neurology 89(1):38\u201345. https:\/\/doi.org\/10.1212\/WNL.0000000000004060","journal-title":"Neurology"},{"issue":"2","key":"12803_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/1352458518820759","volume":"26","author":"E Pagani","year":"2020","unstructured":"Pagani E, Rocca MA, De Meo E et al (2020) Structural connectivity in multiple sclerosis and modeling of disconnection. Mult Scler Houndmills Basingstoke Engl 26(2):220\u2013232. https:\/\/doi.org\/10.1177\/1352458518820759","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"3","key":"12803_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41582-020-00439-8","volume":"17","author":"DT Chard","year":"2021","unstructured":"Chard DT, Alahmadi AAS, Audoin B et al (2021) Mind the gap: from neurons to networks to outcomes in multiple sclerosis. Nat Rev Neurol 17(3):173\u2013184. https:\/\/doi.org\/10.1038\/s41582-020-00439-8","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"12803_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/ana.26440","volume":"92","author":"FC Oertel","year":"2022","unstructured":"Oertel FC, Sotirchos ES, Zimmermann HG et al (2022) Longitudinal retinal changes in MOGAD. Ann Neurol 92(3):476\u2013485. https:\/\/doi.org\/10.1002\/ana.26440","journal-title":"Ann Neurol"},{"key":"12803_CR22","doi-asserted-by":"publisher","unstructured":"Ringelstein M, Harmel J, Zimmermann H, et al (2020) Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000008684","DOI":"10.1212\/WNL.0000000000008684"},{"issue":"12","key":"12803_CR23","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/jnnp-2018-318382","volume":"89","author":"FC Oertel","year":"2018","unstructured":"Oertel FC, Havla J, Roca-Fern\u00e1ndez A et al (2018) Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry 89(12):1259\u20131265. https:\/\/doi.org\/10.1136\/jnnp-2018-318382","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"12803_CR24","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.1212\/WNL.0000000000200052","volume":"98","author":"MW H\u00fcmmert","year":"2022","unstructured":"H\u00fcmmert MW, Sch\u00f6ppe LM, Bellmann-Strobl J et al (2022) Costs and health-related quality of life in patients with NMO spectrum disorders and MOG-antibody\u2013associated disease. Neurology 98(11):e1184\u2013e1196. https:\/\/doi.org\/10.1212\/WNL.0000000000200052","journal-title":"Neurology"},{"issue":"3","key":"12803_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000985","volume":"8","author":"I Ayzenberg","year":"2021","unstructured":"Ayzenberg I, Richter D, Henke E et al (2021) Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody-seropositive patients. Neurol Neuroimmunol Neuroinflammation 8(3):e985. https:\/\/doi.org\/10.1212\/NXI.0000000000000985","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"6","key":"12803_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/archneur.58.6.961","volume":"58","author":"JA Cohen","year":"2001","unstructured":"Cohen JA, Cutter GR, Fischer JS et al (2001) Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58(6):961\u2013967. https:\/\/doi.org\/10.1001\/archneur.58.6.961","journal-title":"Arch Neurol"},{"issue":"9","key":"12803_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1212\/01.wnl.0000313034.46883.16","volume":"71","author":"GC Ebers","year":"2008","unstructured":"Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH (2008) Disability as an outcome in MS clinical trials. Neurology 71(9):624\u2013631. https:\/\/doi.org\/10.1212\/01.wnl.0000313034.46883.16","journal-title":"Neurology"},{"issue":"7","key":"12803_CR28","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR et al (2001) Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol Chic Ill 1960 119(7):1050\u20131058. https:\/\/doi.org\/10.1001\/archopht.119.7.1050","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"2","key":"12803_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001126","volume":"9","author":"JS Graves","year":"2021","unstructured":"Graves JS, Oertel FC, Van der Walt A et al (2021) Leveraging visual outcome measures to advance therapy development in neuroimmunologic disorders. Neurol Neuroimmunol Neuroinflamm 9(2):e1126. https:\/\/doi.org\/10.1212\/NXI.0000000000001126","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12803_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","volume":"11","author":"F Schmidt","year":"2017","unstructured":"Schmidt F, Zimmermann H, Mikolajczak J et al (2017) Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 11:45\u201350. https:\/\/doi.org\/10.1016\/j.msard.2016.11.008","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"12803_CR31","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/ene.14729","volume":"28","author":"S Asseyer","year":"2021","unstructured":"Asseyer S, Henke E, Trebst C et al (2021) Pain, depression, and quality of life in adults with MOG-antibody\u2013associated disease. Eur J Neurol 28(5):1645\u20131658. https:\/\/doi.org\/10.1111\/ene.14729","journal-title":"Eur J Neurol"},{"issue":"11","key":"12803_CR32","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"issue":"Suppl 3","key":"12803_CR33","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1212\/WNL.0b013e3181dbb571","volume":"74","author":"CH Polman","year":"2010","unstructured":"Polman CH, Rudick RA (2010) The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology 74(Suppl 3):S8-15. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dbb571","journal-title":"Neurology"},{"issue":"6","key":"12803_CR34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ajo.2006.06.060","volume":"142","author":"BA Raphael","year":"2006","unstructured":"Raphael BA, Galetta KM, Jacobs DA et al (2006) Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol 142(6):1026\u20131035. https:\/\/doi.org\/10.1016\/j.ajo.2006.06.060","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"12803_CR35","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1055\/s-0029-1246062","volume":"228","author":"C Wagenbreth","year":"2011","unstructured":"Wagenbreth C, Sabel BA, T\u00f6nnies S, Gall C (2011) The neuroophthalmic supplement to the NEI-VFQ: test statistics and validation with a cohort of patients with pre- and postchiasmatic damage. Klin Monatsbl Augenheilkd 228(11):971\u2013978. https:\/\/doi.org\/10.1055\/s-0029-1246062","journal-title":"Klin Monatsbl Augenheilkd"},{"issue":"9","key":"12803_CR36","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","volume":"87","author":"P Waters","year":"2016","unstructured":"Waters P, Reindl M, Saiz A et al (2016) Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 87(9):1005\u20131015. https:\/\/doi.org\/10.1136\/jnnp-2015-312601","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"12803_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000674","volume":"7","author":"M Reindl","year":"2020","unstructured":"Reindl M, Schanda K, Woodhall M et al (2020) International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 7(2):e674. https:\/\/doi.org\/10.1212\/NXI.0000000000000674","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"12803_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"issue":"1","key":"12803_CR39","doi-asserted-by":"publisher","first-page":"8465","DOI":"10.1038\/s41598-022-12425-9","volume":"12","author":"P Gupta","year":"2022","unstructured":"Gupta P, Fenwick EK, Man REK et al (2022) Different impact of early and late stages irreversible eye diseases on vision-specific quality of life domains. Sci Rep 12(1):8465. https:\/\/doi.org\/10.1038\/s41598-022-12425-9","journal-title":"Sci Rep"},{"key":"12803_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12955-016-0569-5","volume":"14","author":"A Ousmen","year":"2016","unstructured":"Ousmen A, Conroy T, Guillemin F et al (2016) Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time. Health Qual Life Outcomes 14:167. https:\/\/doi.org\/10.1186\/s12955-016-0569-5","journal-title":"Health Qual Life Outcomes"},{"key":"12803_CR41","doi-asserted-by":"publisher","unstructured":"Duchow A, Bellmann\u2010Strobl J, Friede T, et al (2024) Time to disability milestones and annualized relapse rates in NMOSD and MOGAD. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.26858","DOI":"10.1002\/ana.26858"},{"key":"12803_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12666-w","author":"T Pakeerathan","year":"2024","unstructured":"Pakeerathan T, Havla J, Schwake C et al (2024) Rapid differentiation of MOGAD and MS after a single optic neuritis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-024-12666-w","journal-title":"J Neurol"},{"issue":"3","key":"12803_CR43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/ane.12881","volume":"137","author":"C Heesen","year":"2018","unstructured":"Heesen C, Haase R, Melzig S et al (2018) Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand 137(3):356\u2013362. https:\/\/doi.org\/10.1111\/ane.12881","journal-title":"Acta Neurol Scand"},{"key":"12803_CR44","doi-asserted-by":"publisher","unstructured":"Vingopoulos F, Bannerman A, Zhou P, et al (2023) Towards the validation of quantitative contrast sensitivity as a clinical endpoint: correlations with vision-related quality of life in bilateral AMD. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjo-2023-323507","DOI":"10.1136\/bjo-2023-323507"},{"issue":"5","key":"12803_CR45","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00417-021-05434-3","volume":"260","author":"S Szegedi","year":"2022","unstructured":"Szegedi S, Boltz A, Scharinger EM, V\u00e9csei-Marlovits PV (2022) Quality of life in patients with glaucoma assessed by 39-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-39). Graefes Arch Clin Exp Ophthalmol 260(5):1623\u20131631. https:\/\/doi.org\/10.1007\/s00417-021-05434-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"12803_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/brain\/awu335","volume":"138","author":"LJ Balcer","year":"2015","unstructured":"Balcer LJ, Miller DH, Reingold SC, Cohen JA (2015) Vision and vision-related outcome measures in multiple sclerosis. Brain 138(1):11\u201327. https:\/\/doi.org\/10.1093\/brain\/awu335","journal-title":"Brain"},{"key":"12803_CR47","doi-asserted-by":"publisher","unstructured":"Malmusi D, Artazcoz L, Benach J, Borrell C (2012) Perception or real illness? How chronic conditions contribute to gender inequalities in self-rated health. Eur J Public Health 22(6):781\u2013786. https:\/\/doi.org\/10.1093\/eurpub\/ckr184","DOI":"10.1093\/eurpub\/ckr184"},{"issue":"1","key":"12803_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12875-016-0440-0","volume":"17","author":"AE Thompson","year":"2016","unstructured":"Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K (2016) The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Fam Pract 17(1):38. https:\/\/doi.org\/10.1186\/s12875-016-0440-0","journal-title":"BMC Fam Pract"},{"issue":"2","key":"12803_CR49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/02813432.2023.2191653","volume":"41","author":"AV Ballering","year":"2023","unstructured":"Ballering AV, Olde Hartman TC, Verheij R, Rosmalen JGM (2023) Sex and gender differences in primary care help-seeking for common somatic symptoms: a longitudinal study. Scand J Prim Health Care 41(2):132\u2013139. https:\/\/doi.org\/10.1080\/02813432.2023.2191653","journal-title":"Scand J Prim Health Care"},{"key":"12803_CR50","doi-asserted-by":"crossref","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22(3):268\u2013282","DOI":"10.1016\/S1474-4422(22)00431-8"},{"issue":"8","key":"12803_CR51","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/OPX.0b013e3181e61bd8","volume":"87","author":"BE Dougherty","year":"2010","unstructured":"Dougherty BE, Bullimore MA (2010) Comparison of scoring approaches for the NEI VFQ-25 in low vision. Optometry Vis 87(8):543\u2013548. https:\/\/doi.org\/10.1097\/OPX.0b013e3181e61bd8","journal-title":"Optometry Vis"},{"key":"12803_CR52","doi-asserted-by":"publisher","first-page":"205521731559618","DOI":"10.1177\/2055217315596184","volume":"1","author":"JP Stellmann","year":"2015","unstructured":"Stellmann JP, Young KL, P\u00f6ttgen J, Dorr M, Heesen C (2015) Introducing a new method to assess vision: computer-adaptive contrast-sensitivity testing predicts visual functioning better than charts in multiple sclerosis patients. Mult Scler J Exp Transl Clin 1:2055217315596184. https:\/\/doi.org\/10.1177\/2055217315596184","journal-title":"Mult Scler J Exp Transl Clin"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12803-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12803-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12803-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:57:15Z","timestamp":1738173435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12803-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["12803"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12803-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MN: no conflict of interest. VH: received research support from NEMOS e.V. independent of this project. FP: received research support from NeuroCure Clinical Research Center, the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche; received consulting fees from Alexion, Roche, Horizon, Neuraxpharm and speaker honoraria from Almirall, Bayer, Biogen, GlaxoSmithKline, Hexal, Merck, Sanofi Genzyme, Novartis, Viela Bio, UCB, Mitsubishi Tanabe, Celgene, Guthy Jackson Foundation, Serono, Roche. He received travel grants from Merck, Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe, Celgene. He participated on Data Safety Monitoring Board at Celgene AdBoard, Roche AdBoard, UCB AdBoard, Merck AdBoard Academic Editor PLos One, Celgene AdBoard, Roche AdBoard, UCB AdBoard, Merck AdBoard Academic Editor PLos One. He is Academic Editor at PLoS ONE and Associate Editor of Neurology\u00ae Neuroimmunology and Neuroinflammation. FCO: currently received research support by Deutsche Forschungsgemeinschaft (DFG), Hertie foundation and Novartis\u2014all unrelated to this project. She further received fellowship support from the American Academy of Neurology (AAN) and the National MS Society (NMSS) and travel support for the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) in the recent past, also unrelated to this project. PS: received travel support by UCB and received speaker\u2019s honoraria by Roche and Alexion and served on advisory board by Alexion. JBS: received institutional research support from NEMOS e.V., Alexion and Bayer AG, personal compensation from Alexion, speaking honoraria and travel grants from Bayer Healthcare, Horizon\/Amgen, Novartis and Sanofi-Aventis\/Genzyme, in addition received compensation for serving on a scientific advisory board of Alexion, Roche and Merck, all unrelated to the presented work. ESA: received research grants from Novartis and Roche, speaker honoraria from Alexion, Amgen, Bayer and Roche, unrelated to the presented work. MK: received grants from Merck and Novartis, travel support and personal fees from Alexion, BMS, Merck, Novartis, Roche and Sanofi, all unrelated to the presented work. MWH: received institutional research support from Myelitis e. V., speaker honoraria from selpers og, Horizon, and Alexion, and travel grants and compensation for serving on an advisory board from Alexion. None of this interfered with the current manuscript. FB: no conflict of interest. DT: no conflict of interest. CT: received honoraria for consultation and expert testimony from Alexion Pharma Germany GmbH. None of this interfered with the current work. CS: received speaker honoraria from Alexion, Argenx, Desitin and TAD and served on advisory board for Alexion and Argenx, none related to this study. IA: received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities- from Roche, Horizon, Alexion, Sanofi, Merck, and received research support from Diamed, Roche and Alexion, none related to this study. CS: received speaker honoraria from Alexion and travel support from Novartis and UCB, all not related to the content of this manuscript. TP: no conflict of interest. KF: no conflict of interest. OA: reports grants from the German Ministry of Education and Research (BMBF) and the German Research Foundation (DFG); grants and personal fees from Biogen and Novartis; and travel support and personal fees from Alexion, Almirall, MedImmune, Merck Serono, Roche, Sanofi, Viela Bio\/Horizon Therapeutics and Zambon. MR: received speaker honoraria from Novartis, Bayer Vital GmbH, Roche, Alexion, Horizon and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, Roche, Horizon, Alexion and Merck, none related to this study. MK: received honoraria from Chugai Pharma, Roche Pharma and Novartis with no relation to the content of the article. CW: received institutional support from Novartis, Biogen, Alexion, Janssen, Hexal and Roche. MG: received consulting and\/or speaker honoraria from Biogen, BMS, JJ, Merck, Novartis, Roche, Sanofi Genzyme and Teva. MK: no conflict of interest. KA: received travel support (till 2014) from Alexion, Bayer, BiogenIdec, MerckSerono, Novartis, Teva and honoria from Biogen und TEVA; he supported neuroimmunological studies for Alexion, Bayer, BiogenIdec, MerckSerono, Roche and Novartis. PK: no conflict of interest. IK: received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Almirall, Bayer, Biogen, GlaxoSmithKline, Hexal, Horizon, Merck, Neuraxpharm, Roche\/Chugai and Sanofi. PR: speaker or Consultant Honorary from Alexion (Astra Zeneca), Allmiral, Amicus, Biogen, Horizon (Amgen), Merck, Novartis, Sandoz, Sanofi, Roche, Teva. Received research grants from Amicus, Merck, Roche, Austrian Science Fund (FWF). AW: received speaker honoraria, consultant fees and travel reimbursement from Alexion, Bayer, Biogen, Glaxo Smith Kline, Hexal, Janssen, Merck, Novartis, Pfizer, Roche and Sanofi Genzyme, none related to this study. AW: no conflict of interest. MSW: no conflict of interest. JW: no conflict of interest. KG: reports reimbursement of travelling expenses by UCB. FTB: received, over his academic career, research support and travel grants to attend scientific meetings, through his institution, from the German Science Fund (DFG), German Federal Ministry of Education and Science (BMBF), Bayer-Schering, Diamed, Fresenius, Merck, Novartis, Pfizer, Roche, Sanofi and Teva; speaker fees and compensation for advisory boards from Actelion, Alexion, Bayer, Biogen, CSL Behring, Fresenius, Horizon, Merck, Novartis, Roche, Sanofi-Genzyme, Takeda and Teva. None of these are related to this work. MS: received consulting and\/or speaker honoraria from Alexion, Bayer, Biogen, Bristol-Myers-Squibb\/Celgene, Janssen, Merck, Horizon, Roche, and Sanofi Genzyme. HT: participated in meetings sponsored by or received honoraria for acting as an advisor\/speaker for Alexion, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Diamed, Fresenius, Fujirebio, GlaxoSmithKline, Horizon, Janssen-Cilag, Merck, Novartis, Roche, Sanofi-Genzyme, Siemens, and Teva. He also acknowledges research support by DMSG (German Multiple Sclerosis Society), MWK-BW (Ministry of Science, Research and Arts of the State Baden-W\u00fcrttemberg), University of Ulm, and Chemische Fabrik Karl Bucher. IV: received travel support from Alexion. ED: no conflict of interest. LR: no conflict of interest. LK: received compensation for serving on Scientific Advisory Boards for Alexion, Genzyme, Janssen, Merck, Novartis, and Roche; she received speaker honoraria and travel support from Bayer, Biogen, Genzyme, Grifols, Merck, Novartis, Roche, Santhera, and Teva; she receives research support from DFG, the German Ministry for Education and Research (BMBF), the IZKF M\u00fcnster, IMF M\u00fcnster, Biogen, Novartis and Merck. MKK: received speaker honoraria from BMS, Merck and Novartis. SJ: no conflict of interest. BW: received research grants from Deutsche Forschungsgemeinschaft, German Ministry of Education and Research, Dietmar Hopp Foundation, Klaus Tschira Foundation, Novartis, Roche, and personal fees from Alexion, INSTAND, Novartis, Roche, all unrelated to this work. JAG: received a research grant from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; SFB\/TRR 274, ID 408885537) and reports travel expenses and non-financial support from Merck, outside the submitted work. TK: received speaker honoraria and\/or personal fees for advisory boards from Novartis Pharma, Roche Pharma, Alexion\/Astra Zeneca, Horizon Therapeutics\/Amgen, Merck, Chugai Pharma and Biogen. The Institution she works for has received compensation for serving as a member of a steering committee from Roche. Furthermore, she is a site principal investigator in several randomized clinical trials and her institution has received compensation for clinical trials from Novartis Pharma, Roche Pharma and Sanofi Genzyme, all outside the present work. DE: received speaker honoraria and\/or travel reimbursement from Alexion, Amgen\/Horizon and Merck, all not related to this work. JH: reports a grant for OCT research from the Friedrich\u2010Baur\u2010Stiftung, Horizon and Merck, personal fees and nonfinancial support from Alexion, Amgen, Bayer, Biogen, BMS, Merck, Novartis and Roche, and nonfinancial support of the Sumaira Foundation and Guthy-Jackson Charitable Foundation, all outside the submitted work. NS: no conflict of interest. JPS: no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data collection and its usage for the purpose of this publication was approved by the ethics committees of all NEMOS centres. For the MS and control data, we obtained ethical approval from the local ethic committee of Hamburg Chamber of Physicians (Registration Number PV5557). Also, written informed consent was obtained from all patients before entering the registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"86"}}